OraSure pushes HIV test
This article was originally published in The Tan Sheet
Executive Summary
OraSure Technologies continues to seek FDA approval of its OraQuick HIV OTC over-the-counter test based on feedback from a closed-door FDA advisory panel session, the firm says Nov. 18. During a Nov. 17 meeting of FDA's Blood Products Advisory Committee to discuss over-the-counter, home-use HIV test kits, the panel met privately with OraSure to review the results of ongoing clinical studies for its OTC test, and discuss what additional clinical data FDA needs for approval. The firm already markets the OraQuick Advance rapid HIV-12 antibody test, among others
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.